Paradigm Biopharmaceuticals Future Growth
Future criteria checks 3/6
Paradigm Biopharmaceuticals is forecast to grow earnings and revenue by 111.4% and 149.4% per annum respectively. EPS is expected to grow by 99% per annum. Return on equity is forecast to be -29.4% in 3 years.
Key information
111.4%
Earnings growth rate
98.96%
EPS growth rate
| Biotechs earnings growth | 39.0% |
| Revenue growth rate | 149.4% |
| Future return on equity | -29.41% |
| Analyst coverage | Low |
| Last updated | 28 Apr 2026 |
Recent future growth updates
Recent updates
Phase III research update, interview with Dr. Rennie
Below is a buy-side style investment memo built directly from the provided video transcript using Copilot Investment Memo – Paradigm Biopharmaceuticals (ASX: PAR) 1. Executive Summary Paradigm Biopharmaceuticals is a late-stage biotech company developing injectable pentosan polysulfate sodium (iPPS) for osteoarthritis (OA), targeting both symptom relief (pain/function) and potential disease modification.I am a shareholder and my investment thesis is maintained
Below is a fact-checked, integrated investment memo on Paradigm Biopharmaceuticals (ASX: PAR), made with copilot help, (if you find any errors, please let me know); combining validation of AmirV claims with external sources and a professional investment framework. Investment Memo: Paradigm Biopharmaceuticals (ASX: PAR) Ticker: PAR (ASX) Sector: Biotechnology (Late-stage clinical) Core Asset: Zilosul® (injectable pentosan polysulfate sodium, PPS) Date: May 2026 1.Weekly Picks: 💻 A Hedge Against US Government Shutdown And 2 More Picks
This week’s picks cover: How UPS plans to cut costs and automate its way back to profitability, why Paradigm Biopharma could soar if its osteoarthritis drug wins FDA approval, and how Barrick Mining offers a hedge against U.S. fiscal chaos
Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success
Paradigm Biopharmaceuticals (ASX: PAR) on Cusp of Transformation with Potential FDA Approval of Osteoarthritis Drug Zilosul® Melbourne, Australia - Paradigm Biopharmaceuticals (ASX: PAR), a late-stage drug development company, is poised at a critical juncture as it progresses its lead drug candidate, Zilosul® (injectable pentosan polysulfate sodium), through Phase 3 clinical trials for the treatment of osteoarthritis (OA). A successful outcome and subsequent clearance from the U.S. Food and Drug Administration (FDA) could unlock a multi-billion dollar market and fundamentally reshape the company's future, offering a new treatment paradigm for millions suffering from the debilitating joint disease.We're Keeping An Eye On Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Paradigm...We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?
Paradigm Biopharmaceuticals Limited ( ASX:PAR ) shareholders have seen the share price descend 15% over the month. But...When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?
We feel now is a pretty good time to analyse Paradigm Biopharmaceuticals Limited's (ASX:PAR) business as it appears...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2028 | 520 | 111 | N/A | 248 | 1 |
| 6/30/2027 | N/A | -24 | N/A | -23 | 1 |
| 6/30/2026 | N/A | -24 | N/A | -23 | 1 |
| 12/31/2025 | 0 | -36 | -28 | -27 | N/A |
| 9/30/2025 | 0 | -27 | -22 | -22 | N/A |
| 6/30/2025 | N/A | -19 | -16 | -16 | N/A |
| 3/31/2025 | 0 | -17 | -20 | -20 | N/A |
| 12/31/2024 | 0 | -15 | -23 | -23 | N/A |
| 9/30/2024 | 0 | -37 | -45 | -45 | N/A |
| 6/30/2024 | N/A | -59 | -66 | -66 | N/A |
| 3/31/2024 | 0 | -64 | -72 | -72 | N/A |
| 12/31/2023 | 0 | -70 | -78 | -78 | N/A |
| 9/30/2023 | 0 | -61 | -62 | -62 | N/A |
| 6/30/2023 | N/A | -52 | -45 | -45 | N/A |
| 3/31/2023 | 0 | -48 | -39 | -39 | N/A |
| 12/31/2022 | 0 | -44 | -33 | -33 | N/A |
| 9/30/2022 | 0 | -42 | -33 | -33 | N/A |
| 6/30/2022 | 0 | -39 | -32 | -32 | N/A |
| 3/31/2022 | 0 | -40 | -32 | -32 | N/A |
| 12/31/2021 | 0 | -41 | -32 | -32 | N/A |
| 9/30/2021 | 0 | -37 | -34 | -34 | N/A |
| 6/30/2021 | 0 | -34 | -35 | -35 | N/A |
| 3/31/2021 | 0 | -31 | -29 | -29 | N/A |
| 12/31/2020 | -1 | -28 | -24 | -23 | N/A |
| 9/30/2020 | 0 | -20 | -17 | -17 | N/A |
| 6/30/2020 | N/A | -12 | -10 | -10 | N/A |
| 3/31/2020 | 2 | -14 | -10 | -10 | N/A |
| 12/31/2019 | 4 | -16 | -10 | -10 | N/A |
| 9/30/2019 | 3 | -16 | N/A | -8 | N/A |
| 6/30/2019 | 3 | -16 | N/A | -6 | N/A |
| 3/31/2019 | 3 | -11 | N/A | -7 | N/A |
| 12/31/2018 | 3 | -7 | N/A | -7 | N/A |
| 9/30/2018 | 3 | -7 | N/A | -6 | N/A |
| 6/30/2018 | 3 | -6 | N/A | -6 | N/A |
| 3/31/2018 | 2 | -6 | N/A | -4 | N/A |
| 12/31/2017 | 2 | -5 | N/A | -3 | N/A |
| 9/30/2017 | 2 | -5 | N/A | -4 | N/A |
| 6/30/2017 | 2 | -4 | N/A | -4 | N/A |
| 3/31/2017 | 2 | -4 | N/A | -5 | N/A |
| 12/31/2016 | 1 | -4 | N/A | -6 | N/A |
| 9/30/2016 | 1 | -4 | N/A | -5 | N/A |
| 6/30/2016 | 1 | -3 | N/A | -4 | N/A |
| 3/31/2016 | 1 | -3 | N/A | -3 | N/A |
| 12/31/2015 | 0 | -2 | N/A | -1 | N/A |
| 9/30/2015 | 0 | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PAR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.6%).
Earnings vs Market: PAR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PAR is expected to become profitable in the next 3 years.
Revenue vs Market: PAR is forecast to have no revenue next year.
High Growth Revenue: PAR is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PAR is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 00:57 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Paradigm Biopharmaceuticals Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Soo Romanoff | Edison Investment Research |
| Arron Aatkar | Edison Investment Research |
| null null | Lodge Partners Pty Ltd. |